LB-100 is under clinical development by Lixte Biotechnology and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LB-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LB-100 overview
LB-100 is under development for the treatment of soft tissue sarcoma, recurrent glioblastoma multiforme, del5q myelodysplastic syndrome, advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosarcoma, or malignant nerve sheath tumor), small cell lung cancer ovarian clear cell carcinoma, peritoneal cancer and fallopian tube cancer. It is a synthetic derivative of cantharidin. The drug candidate is administered through intravenous route and oral route. It acts by targeting protein phosphatase 2A (PP2A).
It was also under development for the treatment of solid tumors including colon cancer, pancreatic cancer, breast cancer, carcinoid tumor, testicular cancer, duodenal cancer, non-small cell lung cancer, thymoma, hepatocellular carcinoma (HCC), pheochromocytoma, sarcoma, melanoma, insulin resistance, acute ischemia of brain, septic shock, depression, myocardial ischemia, post-traumatic stress disorder (PTSD),type 2 diabetes, Angelman syndrome, triple negative breast cancer, metastatic colorectal cancer, achondroplasia and obesity.
Lixte Biotechnology overview
Lixte Biotechnology (Lixte) is a drug discovery company, which focuses on the discovery and development of novel drugs for the treatment of cancer and non-cancer diseases using its biomarker technology. It develops two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as small lung cancer, soft tissue sarcoma, myelodysplastic syndrome, and glimos among others. Lixte primarly operates in the US and has collaborations with academic centers, contract research organizations and pharmaceutical companies for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.
For a complete picture of LB-100’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
